Meta Biomed Launches "RENUVOL" at IMCAS 2026, Accelerates Global Market Expansion

Biomedical company Meta Biomed announced on the 24th that it successfully held a launch seminar for its new product "RENUVOL" at the "IMCAS World Congress 2026," a world-renowned international aesthetic and plastic surgery conference being held in Paris, France, through the 31st.

The newly unveiled RENUVOL is a skin booster with a composite structure that combines PN (Polynucleotide) and antioxidant ingredients based on PDO (Polydioxanone). It is characterized by being designed with a focus on the stability of the active ingredients and the efficiency of their delivery.

The company explained that it has strengthened the product’s competitiveness based on the PDO technology that Meta Biomed has accumulated over the years. The launch seminar was held with the participation of about 70 global medical professionals. Brazilian dermatologist Dr. Clara Santos and Choi Kyungmin, CEO of technology partner LabInCube, took part as speakers and gave presentations focusing on the product’s mechanism of action, treatment protocols, utilization strategies by treatment area, and clinical cases. In particular, discussions on actual treatment outcomes and patient satisfaction drew strong interest from medical professionals on site.

After the seminar, active consultations and collaboration discussions on the product were held with medical professionals and industry officials from various countries. Existing overseas buyers discussed ways to expand distribution of the new product, and the company also achieved results by signing new contracts with buyers from the Middle East region, including Europe.

During the event, Meta Biomed President Oh Jisoo discussed future cooperation strategies with global partners, and the company plans to accelerate its entry into the European and Asian markets through active marketing focused on overseas exhibitions and academic conferences.

A Meta Biomed representative said, "Through this IMCAS launch seminar, we were able to effectively communicate the characteristics and clinical value of Meta Biomed’s PDO technology to global medical professionals," adding, "Based on our technological collaboration with LabInCube, we will continue to expand our presence in the global aesthetic medical market."